中韩高清无专码区2021曰_色翁荡熄又大又硬又粗又视频图片_波多野结衣乳巨码无在线观看_国产91福利在线播放_国产人妻人伦精品_马来西亚潜水天堂_黄色免费网站下载_免费看黄网站黄污污污热门软件_小莹客厅激情46章至50章视频

Jiangsu Bio-Sincere Pharmaceutical Technology Co., Ltd. is an innovative pharmaceutical company driven by drug research and development to propel the entire pharmaceutical industry chain. It primarily focuses on the research and development of 505(b)(2) category improved new drugs and high-end specialized generic drugs. The company possesses advanced technology platforms, including a novel nanomicellar drug delivery system and an artificial intelligence and transcriptome big data platform. It provides domestic and international clients with technology transfer and contract research and development services for new drugs and generic drugs, comprehensively building the company's core competitiveness.

Strong R&D Capabilities

Rich Industrial Resource Advantages: The core team has nearly two decades of deep experience in the biopharmaceutical industry, possessing substantial industrial resources and top-tier project establishment, research, and development experience and capabilities in China.

Exclusive Technology Platform Advantages: The big data platform and micellar platform are exclusively owned by Bio-Sincere, enabling rapid, low-cost, and systematic development of new uses for existing drugs.

Differentiated Layout Strategy

Based on the Marketing Authorization Holder (MAH) system, the company combines Contract Manufacturing Organization (CMO) and Contract Sales Organization (CSO) approaches to develop and market self-owned improved new drugs and generic drugs, while also providing drug contract research and development services externally. With 505(b)(2) improved new drugs as the flagship and high-end specialized generic drugs as supplements, the company ensures strong certainty for product market entry.